Assessing the Financial Sustainability of a Virtual Clinic Providing Comprehensive Diabetes Care.

IF 3.7 Q2 ENDOCRINOLOGY & METABOLISM
Paul Dupenloup, Grace Guan, Grazia Aleppo, Richard M Bergenstal, Korey Hood, Davida Kruger, Teresa McArthur, Beth Olson, Sean Oser, Tamara Oser, Ruth S Weinstock, Robin L Gal, Craig Kollman, David Scheinker
{"title":"Assessing the Financial Sustainability of a Virtual Clinic Providing Comprehensive Diabetes Care.","authors":"Paul Dupenloup, Grace Guan, Grazia Aleppo, Richard M Bergenstal, Korey Hood, Davida Kruger, Teresa McArthur, Beth Olson, Sean Oser, Tamara Oser, Ruth S Weinstock, Robin L Gal, Craig Kollman, David Scheinker","doi":"10.1177/19322968251340664","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The Virtual Diabetes Specialty Clinic (VDiSC) study demonstrated the feasibility of providing comprehensive diabetes care entirely virtually by combining virtual visits with continuous glucose monitoring support and remote patient monitoring (RPM). However, the financial sustainability of this model remains uncertain.</p><p><strong>Methods: </strong>We developed a financial model to estimate the variable costs and revenues of virtual diabetes care, using visit data from the 234 VDiSC participants with type 1 or type 2 diabetes. Data included virtual visits with certified diabetes care and education specialists (CDCES), endocrinologists, and behavioral health services (BHS). The model estimated care utilization, variable costs, reimbursement revenue, gross profit, and gross profit margin per member, per month (PMPM) for privately insured, publicly insured, and overall clinic populations (75% privately insured). We performed two-way sensitivity analyses on key parameters.</p><p><strong>Results: </strong>Gross profit and gross profit margin PMPM (95% confidence interval) were estimated at $-4 ($-14.00 to $5.68) and -4% (-3% to -6%) for publicly insured patients; $267.26 ($256.59-$277.93) and 73% (58%-88%) for privately insured patients; and $199.41 ($58.43-$340.39) and 67% (32%-102%) for the overall clinic. Profits were primarily driven by CDCES visits and RPM. Results were sensitive to insurance mix, cost-to-charge ratio, and commercial-to-Medicare price ratio.</p><p><strong>Conclusions: </strong>Virtual diabetes care can be financially viable, although profitability relies on privately insured patients. The analysis excluded fixed costs of clinic infrastructure, and securing reimbursement may be challenging in practice. The financial model is adaptable to various care settings and can serve as a planning tool for virtual diabetes clinics.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968251340664"},"PeriodicalIF":3.7000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075182/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19322968251340664","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The Virtual Diabetes Specialty Clinic (VDiSC) study demonstrated the feasibility of providing comprehensive diabetes care entirely virtually by combining virtual visits with continuous glucose monitoring support and remote patient monitoring (RPM). However, the financial sustainability of this model remains uncertain.

Methods: We developed a financial model to estimate the variable costs and revenues of virtual diabetes care, using visit data from the 234 VDiSC participants with type 1 or type 2 diabetes. Data included virtual visits with certified diabetes care and education specialists (CDCES), endocrinologists, and behavioral health services (BHS). The model estimated care utilization, variable costs, reimbursement revenue, gross profit, and gross profit margin per member, per month (PMPM) for privately insured, publicly insured, and overall clinic populations (75% privately insured). We performed two-way sensitivity analyses on key parameters.

Results: Gross profit and gross profit margin PMPM (95% confidence interval) were estimated at $-4 ($-14.00 to $5.68) and -4% (-3% to -6%) for publicly insured patients; $267.26 ($256.59-$277.93) and 73% (58%-88%) for privately insured patients; and $199.41 ($58.43-$340.39) and 67% (32%-102%) for the overall clinic. Profits were primarily driven by CDCES visits and RPM. Results were sensitive to insurance mix, cost-to-charge ratio, and commercial-to-Medicare price ratio.

Conclusions: Virtual diabetes care can be financially viable, although profitability relies on privately insured patients. The analysis excluded fixed costs of clinic infrastructure, and securing reimbursement may be challenging in practice. The financial model is adaptable to various care settings and can serve as a planning tool for virtual diabetes clinics.

评估提供全面糖尿病护理的虚拟诊所的财务可持续性。
虚拟糖尿病专科诊所(Virtual Diabetes Specialty Clinic, VDiSC)研究表明,通过将虚拟就诊与连续血糖监测支持和远程患者监测(RPM)相结合,完全虚拟地提供全面糖尿病护理的可行性。然而,这种模式的财务可持续性仍然不确定。方法:我们开发了一个财务模型来估计虚拟糖尿病护理的可变成本和收入,使用234名患有1型或2型糖尿病的VDiSC参与者的访问数据。数据包括与认证糖尿病护理和教育专家(CDCES)、内分泌学家和行为健康服务(BHS)的虚拟访问。该模型估计了私人保险、公共保险和整个诊所人口(75%的私人保险)的护理利用率、可变成本、报销收入、毛利润和每个成员每月毛利率(PMPM)。对关键参数进行双向敏感性分析。结果:公共保险患者的毛利润和毛利率PMPM(95%置信区间)估计为-4美元(-14.00美元至5.68美元)和-4%(-3%至-6%);私人保险患者为267.26美元(256.59美元- 277.93美元)和73% (58%-88%);整个诊所的费用为199.41美元(58.43- 340.39美元)和67%(32%-102%)。利润主要由CDCES访问量和RPM驱动。结果对保险组合、成本收费比和商业医疗保险价格比敏感。结论:虚拟糖尿病护理在经济上是可行的,尽管盈利能力依赖于私人保险患者。该分析排除了诊所基础设施的固定成本,确保报销在实践中可能具有挑战性。该财务模型适用于各种护理环境,可以作为虚拟糖尿病诊所的规划工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Diabetes Science and Technology
Journal of Diabetes Science and Technology Medicine-Internal Medicine
CiteScore
7.50
自引率
12.00%
发文量
148
期刊介绍: The Journal of Diabetes Science and Technology (JDST) is a bi-monthly, peer-reviewed scientific journal published by the Diabetes Technology Society. JDST covers scientific and clinical aspects of diabetes technology including glucose monitoring, insulin and metabolic peptide delivery, the artificial pancreas, digital health, precision medicine, social media, cybersecurity, software for modeling, physiologic monitoring, technology for managing obesity, and diagnostic tests of glycation. The journal also covers the development and use of mobile applications and wireless communication, as well as bioengineered tools such as MEMS, new biomaterials, and nanotechnology to develop new sensors. Articles in JDST cover both basic research and clinical applications of technologies being developed to help people with diabetes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信